You are here

Article Text

Article menu
Download PDFPDF
Podophyllin office therapy against condyloma should be abandoned
  1. Geo von Krogh1,
  2. Eric Longstaff2
  1. 1Department of Dermatovenereology, Karolinska Hospital, 17176, Stockholm, Sweden
  2. 2Pre-clinical Development Services Ltd, Stockport, UK
  1. Dr von Krogh geo.von.krogh{at}ood.ki.se

Abstract

Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin—the purified, standardised active antiwart ingredient of podophyllin—represents safe and effective first line therapy for patients with anogenital warts.

  • podophyllin
  • podophyllotoxin
  • condyloma therapy

https://doi.org/10.1136/sti.77.6.409

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    Linked Articles